Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450289 | 0.76 | NSD2 (0.56) | NSD2 | |
| SCHEMBL21997146 | 0.73 | NSD2 (0.65) | NSD2 | |
| SCHEMBL3450506 | 0.72 | NSD2 (0.56) | NSD2 | |
| SCHEMBL3449971 | 0.72 | CCNE2 (0.42) | NSD2 | |
| SCHEMBL3450479 | 0.70 | ESR1 (0.48) | — | |
| SCHEMBL22411399 | 0.70 | CTSL (0.52) | NSD2 | |
| SCHEMBL4355871 | 0.68 | PDPK1 (0.54) | NSD2 | |
| Hydrochloric Acid SCHEMBL9070436 | 0.68 | KDM4E (0.55) | MERTK | |
| SCHEMBL14518061 | 0.67 | EPHX1 (0.54) | NSD2 | |
| SCHEMBL3917850 | 0.66 | CTSK (0.60) | NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820818-B2 | Heteroaryl nitrile derivatives | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| CN-100509813-C | Hetereoaryl nitrile derivative | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| US-7544688-B2 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2009-06-09 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1678613-A | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| EP-1537111-A1 | HETEREOARYL NITRILE DERIVATIVES | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | NSD2 1737/4885MERTK 865/4885 |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | NSD2 1922/4885MERTK 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.